Clinical features distinguishing lymphoma development in primary Sjögren's syndrome-A retrospective cohort study

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 2, 2013, Pages 171-177

  Risselada, Anna P ^a   Kruize, Aike A ^a   Bijlsma, Johannes W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Lymphoma; Manifestations; Paraneoplastic; Sj gren

Indexed keywords

IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGICAL PARAMETERS; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NODAL MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PAROTID ENLARGEMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURPURA; RETROSPECTIVE STUDY; SJOEGREN SYNDROME;

LYMPHOMA; MANIFESTATIONS; PARANEOPLASTIC; SJÖGREN;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84886091160     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.03.001     Document Type: Article

References (38)

1. Skopouli F.N., Dafni U., Ioannidis J.P.A., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
2. Theander E., Hendriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
3. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
4. Solans-Laqué R., López-Hernandez A., Bosch-Gil J.A., Palacios A., Campillo M., Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 2011, 41:415-423.
5. Ioannidis J.P.A., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's Syndrome. Arthritis Rheum 2002, 46:741-747.
6. Theander E., Manthorpe R., Jacobsson L.T. Mortality and causes of death in primary Sjögren's Syndrome: a prospective cohort study. Arthritis Rheum 2004, 50:1262-1269.
7. Salomonsson S., Jonsson M.V., Skarstein K., Brokstad K.A., Hjelmström P., Wahren-Herlenius M., et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003, 48:3187-3201.
8. Anderson L.G., Cummings N.A., Asofsky R., Hylton M.B., Tarpley T.M., Tomas T.B., et al. Salivary gland immunoglobulin and rheumatoid factor synthesis in Sjögren's syndrome. Natural history and response to treatment. Am J Med 1972, 53:456-463.
9. Bahler D.W., Miklos J.A., Swerdlow S.H. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1998, 89:3335-3344.
10. De Vita S., Boiocchi M., Sorrentino D., Carbone A., Avellini C., Dolcetti R., et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. Arthritis Rheum 1997, 40:318-331.
11. Dong L., Masaki Y., Takegami T., Jin Z.X., Huang C.R., Fukushima T., et al. Clonality analysis of lymphoproliferative disorders in patients with Sjögren's syndrome. Clin Exp Immunol 2007, 150:279-284.
12. Hansen A., Reiter K., Pruss A., Loddenkemper C., Kaufmann O., Jacobi A.M., et al. Dissemination of a Sjögren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene arrangements. Arthritis Rheum 2006, 54:127-137.
13. Tzioufas A.G., Boumba D.S., Skopouli F.N., Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996, 39:767-772.
14. Wooten M.D., Jasin H.E. Vasculitis and lymphoproliferatieve diseases. Semin Arthritis Rheum 1996, 26:564-574.
15. Donfrid M., Apostolski S., Suvajdzić N., Jancović G., Cemericić-Martinović V., Atkinson H.D., et al. Monocytoid B cell lymphoma associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Acta Haematol 2001, 106:130-132.
16. Noguchi M., Mori K., Yamazaki S., Suda K., Sato N., Oshimi K. Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b. Br J Heamatol 2003, 123:600-605.
17. Marfia G.A., Pachatz C., Terracciano C., Leone G., Bernardini S., Bernardi G., et al. Subacute demyelinating polyneuropathy in B-cell lymphoma with IgM antibodies against glycolipid GD1b. Neurol Sci 2005, 26:355-357.
18. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
19. Seror R., Ravaud P., Bowman S.J., Baron G., Tzioufas A., Theander E., et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010, 69:1103-1109.
20. Risselada A.P., Kruize A.A., Bijlsma J.W.J. Clinical applicability of the EULAR Sjögren's Syndrome disease activity index (ESSDAI)-A cumulative ESSDAI score adds in describing disease severity. Ann Rheum Dis 2012, 71:631.
21. Voulgeralis M., Skopouli F.N. Clinical immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol 2007, 32:265-274.
22. Bahler D.W., Swerdlow S.H. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as non-malignant antigen-selected expansions. Blood 1998, 91:1864-1872.
23. Berg A.R., Weisenburger D.D., Linder J., Armitage J.O. Lymphoplasmacytic lymphoma. Report of a case with three monoclonal proteins derived from a single neoplastic clone. Cancer 1986, 57:1794-1797.
24. H genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000, 95:3878-3884.
25. Bende R.F., Aarts W.M., Riedl R.G., de Jong D., Pals S.T., van Noesel C.J.M. Among B cell non-Hodgkin's lymphomas MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005, 201:1229-1241.
26. Martin T., Weber J.C., Levallois H., Labouret N., Soley A., Koenig S., et al. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000, 43:908-916.
27. Fox R.I., Chen P., Carson D.A., Fong S. Expression of a cross-reactive idiotype on rheumatoid factor in patients with Sjögren's syndrome. J Immunol 1986, 136:477-483.
28. Zulman J., Jaffe R., Talal N. Evidence that the malignant lymphoma of Sjögren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med 1987, 299(22):1215-1220.
29. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
30. Sugai S., Konda S., Shoraski Y., Murayama T., Nishikawa T. Non-IgM monoclonal gammopathy in patients with Sjögren's syndrome. Am J Med 1980, 68:861-866.
31. Sugai S., Takaguchi T., Hirose Y., Konaka Y., Shimizu S., Konda S. B-cell malignancy and monoclonal gammopathy, and idiotype of cell surface and serum immunoglobulin. Jpn J Clin Oncol 1983, 13(3):533-542.
32. Fain O., Hamidou M., Cacoub P., Godeau B., Wechsler B., Pariès J., et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007, 57(8):1473-1480.
33. Antoine J.C., Camdessanché J.P. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007, 6:75-86.
34. Ozaki K., Irioka T., Ishida S., Mizusawa H. Bilateral facial nerve palsy caused by a metastatic malignant lymphoma. Intern Med 2011, 50:2247.
35. Sène D., Jallouli M., Lefaucheur J.P., Saadoun D., Costedoat-Calumeau N., Maisonobe T., et al. Peripheral neuropathies associated with primary Sjögren syndrome. Medicine 2011, 90:133-138.
36. Sugai S., Shimizu S., Tachibana J., Imaoka S., Konda S. A high incidence of rheumatoid factor idiotypes in monoclonal proteins in the serum and in lymphoma cells in patients with Sjögren's syndrome. J Autoimmun 1989, 2:471-476.
37. Verbaan H., Carlson J., Eriksson S., Larsson Å., Liedholm R., Manthorpe R., et al. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between Sjögren's syndrome and hepatitis C in Swedish patients. J intern Med 1999, 245:127-132.
38. Kruize A.A., Hené R.J., van der Heide A., Bodeutsch C., de Wilde P.C., van Bijsterveld OP, et al. Long-term follow-up of patients with Sjögren's syndrome. Arthritis Rheum 1996, 39:297-303.